Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
PuraPharm Corp. Ltd. ( (HK:1498) ) just unveiled an update.
PuraPharm Corporation Limited has announced an update on its proposed capital reduction and subdivision of unissued shares. Following the court’s directions, a hearing is scheduled for January 27, 2025, to confirm the capital reduction. If approved, the capital reduction and subdivision are expected to become effective by February 24, 2025, with the commencement of dealings in new ordinary shares on the same day. This move is likely aimed at optimizing the company’s capital structure, potentially impacting its market operations and stakeholder engagement positively.
More about PuraPharm Corp. Ltd.
PuraPharm Corporation Limited is a company incorporated in the Cayman Islands, primarily operating in the pharmaceutical industry. It specializes in the production and distribution of traditional Chinese medicine and related healthcare products, focusing on enhancing health and well-being.
YTD Price Performance: -9.09%
Average Trading Volume: 105,120
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$197.5M
Find detailed analytics on 1498 stock on TipRanks’ Stock Analysis page.
